Cognito is developing novel and innovative therapeutics designed to potentially improve the lives of patients living with neurodegenerative diseases.
Founded on breakthrough research from MIT, Cognito's investigational platform, Spectris, uses non-invasive audiovisual stimulation to evoke specific brain wave activity—particularly gamma waves—with the potential to preserve brain structure, cognition, and function in patients with Alzheimer’s disease.
The company has demonstrated promising results in clinical studies, including significant slowing of disease progression in treated patients. Spectris AD has received FDA Breakthrough Device Designation, and Cognito is advancing its approach across multiple neurodegenerative conditions.